​

Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NBIX Stock Forecast

Neurocrine Biosciences (NBIX) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $186.31, with a high of $230.00 and a low of $140.00. This represents a 14.50% increase from the last price of $162.71.

$100 $130 $160 $190 $220 $250 High: $230 Avg: $186.31 Low: $140 Last Closed Price: $162.71

NBIX Stock Rating

Neurocrine Biosciences stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (86.49%), 5 Hold (13.51%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 37 0 5 32 Strong Sell Sell Hold Buy Strong Buy

NBIX Price Target Upside V Benchmarks

TypeNameUpside
StockNeurocrine Biosciences14.50%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2532
Avg Price Target$217.00$218.20$181.44
Last Closing Price$162.71$162.71$162.71
Upside/Downside33.37%34.10%11.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 264204--28
May, 264194--27
Apr, 264194--27
Mar, 264194--27
Feb, 264194--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 02, 2026Corinne JohnsonGoldman Sachs$213.00$161.0032.30%30.91%
May 21, 2026Jeffrey WalchBernstein$221.00$155.5042.12%35.82%
May 06, 2026Oppenheimer$230.00$135.0670.29%41.36%
May 06, 2026Piper Sandler$207.00$135.0653.27%27.22%
Apr 06, 2026Oppenheimer$220.00$132.4866.06%35.21%
Mar 10, 2026Josh SchimmerCantor Fitzgerald$195.00$130.3949.55%19.85%
Feb 23, 2026Wolfe Research$160.00$128.3824.63%-1.67%
Feb 17, 2026Danielle BrillTruist Financial$140.00$128.988.54%-13.96%
Feb 12, 2026Needham$185.00$125.3847.55%13.70%
Feb 12, 2026Wedbush$151.00$125.0920.71%-7.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 21, 2026BernsteinOutperforminitialise
May 07, 2026Deutsche BankHoldHoldhold
May 06, 2026OppenheimerOutperformOutperformhold
May 06, 2026Piper SandlerOverweightOverweighthold
May 06, 2026CitigroupBuyBuyhold
Mar 10, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 24, 2026RBC CapitalOutperformOutperformhold
Feb 23, 2026Wolfe ResearchOutperforminitialise
Feb 12, 2026WedbushOutperformOutperformhold
Feb 12, 2026CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$1.61$2.56$3.40$4.81---
Avg Forecast$1.78$2.22$2.56$4.05$6.40$8.65$11.24$14.00
High Forecast$1.87$2.34$2.94$4.34$7.44$11.63$15.31$14.86
Low Forecast$1.66$2.05$1.72$3.74$4.77$6.06$7.52$12.83
Surprise %-46.63%-27.48%--16.05%-24.84%---

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.13B$1.49B$1.89B$2.36B$2.86B---
Avg Forecast$1.14B$1.48B$1.89B$2.36B$2.77B$3.24B$3.68B$4.19B
High Forecast$1.18B$1.55B$1.90B$2.37B$2.84B$3.26B$3.71B$4.38B
Low Forecast$1.08B$1.40B$1.77B$2.34B$2.58B$3.22B$3.65B$3.92B
Surprise %-0.35%0.29%-0.12%-0.11%3.23%---

Net Income Forecast

$-2B $-800M $-100M $600M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.60M$154.50M$249.70M$341.30M$478.60M---
Avg Forecast$110.42M$4.14M$249.70M$385.90M$637.97M$898.75M$1.20B$1.41B
High Forecast$138.10M$25.12M$1.67B$438.60M$751.03M$1.18B$1.55B$1.50B
Low Forecast$82.73M$-16.85M$-1.17B$378.03M$482.22M$611.63M$759.47M$1.30B
Surprise %-18.85%3635.85%--11.56%-24.98%---

NBIX Forecast FAQ

Is Neurocrine Biosciences stock a buy?

Neurocrine Biosciences stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurocrine Biosciences is a favorable investment for most analysts.

What is Neurocrine Biosciences's price target?

Neurocrine Biosciences's price target, set by 37 Wall Street analysts, averages $186.31 over the next 12 months. The price target range spans from $140 at the low end to $230 at the high end, suggesting a potential 14.50% change from the previous closing price of $162.71.

How does Neurocrine Biosciences stock forecast compare to its benchmarks?

Neurocrine Biosciences's stock forecast shows a 14.50% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Neurocrine Biosciences over the past three months?

  • June 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.

What is Neurocrine Biosciences’s EPS forecast?

Neurocrine Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $8.65, marking a 79.83% increase from the reported $4.81 in 2025. Estimates for the following years are $11.24 in 2027, and $14 in 2028.

What is Neurocrine Biosciences’s revenue forecast?

Neurocrine Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $3.24B, reflecting a 13.23% increase from the reported $2.86B in 2025. The forecast for 2027 is $3.68B, and $4.19B for 2028.

What is Neurocrine Biosciences’s net income forecast?

Neurocrine Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $898.75M, representing an 87.79% increase from the reported $478.6M in 2025. Projections indicate $1.2B in 2027, and $1.41B in 2028.